Matches in SemOpenAlex for { <https://semopenalex.org/work/W2231393048> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2231393048 endingPage "16528" @default.
- W2231393048 startingPage "16528" @default.
- W2231393048 abstract "16528 Background: To evaluate the safety and efficacy of bevacizumab alone or in combination therapy in heavily pretreated patients with ovarian cancer. Methods: We identified patients not participating in an ongoing clinical trial who received bevacizumab. Response was retrospectively assessed by CA125 criteria. Complete response (CR) was defined as normalization of serum levels to ≤ 35 U/mL. Partial response (PR) was defined as a ≥50% decrease after initiation of treatment confirmed 28 days apart. Adverse events were prospectively categorized using the common terminology criteria version 3.0. Progression-free and overall survival (PFS and OS) was estimated using Kaplan-Meier method with log-rank test where indicated. Results: Forty-nine patients were identified. The patients were pretreated with a median of 6 (range 1–15) prior chemotherapy regimens including a median of 2 (range 1–6) platinum based regimens. Twenty-two (45%) patients received bevacizumab alone and 27 (55%) received varied combination cytotoxic chemotherapy. Patients received bevacizumab therapy for a median 4.6 months (range 0–27 months). Twenty-two (45%) patients received 10 mg/kg every 2 weeks, while 16 (33%) patients received 15 mg/kg every 3 weeks. Eleven (22%) received both dosing schedules. CTC grade 3 and 4 toxicities occurred in 7 (14.3%) different patients. Toxicities included: 2 (4%) gastrointestinal (GI) perforation, 3 (6%) grade 3 HTN, 1 (2%) transient ischemic attack, and 1 (2%) subarachnoid hemorrhage, Thirty-four patients were evaluable for overall CA-125 response rate (ORR), which included both CR and PR. The ORR for this cohort was 47.1%. The ORR for those who received bevacizumab alone was 30% compared to 65% for those treated with bevacizumab in combination with cytotoxic chemotherapy (P = 0.04). The median PFS for the entire group was 4.6 months (95% CI: 1.1, 8.2 months). The median OS was 11.0 months (95% CI: 3.9, 18.0 months). Conclusions: Bevacizumab alone or in combination therapy is well tolerated and demonstrates activity in heavily pretreated patients with recurrent ovarian cancer. The GI perforation rate in our study is similar to previously reported. Further study of bev alone or in combination therapy is warranted. No significant financial relationships to disclose." @default.
- W2231393048 created "2016-06-24" @default.
- W2231393048 creator A5005037311 @default.
- W2231393048 creator A5006240593 @default.
- W2231393048 creator A5031546031 @default.
- W2231393048 creator A5032196793 @default.
- W2231393048 creator A5046956876 @default.
- W2231393048 creator A5054602117 @default.
- W2231393048 creator A5073323475 @default.
- W2231393048 creator A5077690076 @default.
- W2231393048 creator A5086908552 @default.
- W2231393048 creator A5090740287 @default.
- W2231393048 date "2008-05-20" @default.
- W2231393048 modified "2023-09-23" @default.
- W2231393048 title "The safety and efficacy of bevacizumab therapy in recurrent ovarian carcinoma" @default.
- W2231393048 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.16528" @default.
- W2231393048 hasPublicationYear "2008" @default.
- W2231393048 type Work @default.
- W2231393048 sameAs 2231393048 @default.
- W2231393048 citedByCount "0" @default.
- W2231393048 crossrefType "journal-article" @default.
- W2231393048 hasAuthorship W2231393048A5005037311 @default.
- W2231393048 hasAuthorship W2231393048A5006240593 @default.
- W2231393048 hasAuthorship W2231393048A5031546031 @default.
- W2231393048 hasAuthorship W2231393048A5032196793 @default.
- W2231393048 hasAuthorship W2231393048A5046956876 @default.
- W2231393048 hasAuthorship W2231393048A5054602117 @default.
- W2231393048 hasAuthorship W2231393048A5073323475 @default.
- W2231393048 hasAuthorship W2231393048A5077690076 @default.
- W2231393048 hasAuthorship W2231393048A5086908552 @default.
- W2231393048 hasAuthorship W2231393048A5090740287 @default.
- W2231393048 hasConcept C121608353 @default.
- W2231393048 hasConcept C126322002 @default.
- W2231393048 hasConcept C141071460 @default.
- W2231393048 hasConcept C191897082 @default.
- W2231393048 hasConcept C192562407 @default.
- W2231393048 hasConcept C197934379 @default.
- W2231393048 hasConcept C2776694085 @default.
- W2231393048 hasConcept C2777793932 @default.
- W2231393048 hasConcept C2777802072 @default.
- W2231393048 hasConcept C2778456384 @default.
- W2231393048 hasConcept C2778527123 @default.
- W2231393048 hasConcept C2780427987 @default.
- W2231393048 hasConcept C71924100 @default.
- W2231393048 hasConcept C90924648 @default.
- W2231393048 hasConceptScore W2231393048C121608353 @default.
- W2231393048 hasConceptScore W2231393048C126322002 @default.
- W2231393048 hasConceptScore W2231393048C141071460 @default.
- W2231393048 hasConceptScore W2231393048C191897082 @default.
- W2231393048 hasConceptScore W2231393048C192562407 @default.
- W2231393048 hasConceptScore W2231393048C197934379 @default.
- W2231393048 hasConceptScore W2231393048C2776694085 @default.
- W2231393048 hasConceptScore W2231393048C2777793932 @default.
- W2231393048 hasConceptScore W2231393048C2777802072 @default.
- W2231393048 hasConceptScore W2231393048C2778456384 @default.
- W2231393048 hasConceptScore W2231393048C2778527123 @default.
- W2231393048 hasConceptScore W2231393048C2780427987 @default.
- W2231393048 hasConceptScore W2231393048C71924100 @default.
- W2231393048 hasConceptScore W2231393048C90924648 @default.
- W2231393048 hasIssue "15_suppl" @default.
- W2231393048 hasLocation W22313930481 @default.
- W2231393048 hasOpenAccess W2231393048 @default.
- W2231393048 hasPrimaryLocation W22313930481 @default.
- W2231393048 hasRelatedWork W1804113097 @default.
- W2231393048 hasRelatedWork W2066508006 @default.
- W2231393048 hasRelatedWork W2163274728 @default.
- W2231393048 hasRelatedWork W2172113847 @default.
- W2231393048 hasRelatedWork W2225638675 @default.
- W2231393048 hasRelatedWork W2376769477 @default.
- W2231393048 hasRelatedWork W3031655345 @default.
- W2231393048 hasRelatedWork W3035857150 @default.
- W2231393048 hasRelatedWork W4226051264 @default.
- W2231393048 hasRelatedWork W4231567388 @default.
- W2231393048 hasVolume "26" @default.
- W2231393048 isParatext "false" @default.
- W2231393048 isRetracted "false" @default.
- W2231393048 magId "2231393048" @default.
- W2231393048 workType "article" @default.